| |
|
|
|
|
|
 |
| |
|
Æ÷¶ó¸¶ÀÌ·Õݼ¿ POLAMYROM CAPS.[Nitrofurantoin]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A14500741]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ݼ¿(2006.11.01)(ÇöÀç¾à°¡)
\4 ¿ø/1ݼ¿(2004.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
»ó´Ü ȸ»ö°ú ÇÏ´Ü Àû»öÀÇ Ä°¼¿Á¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
100CAPS |
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
1. ´ÙÀ½ Áúȯ¿¡ »ç¿ëÇÒ ¼ö ÀÖ´Ù. ¿ä·Î°¨¿°Áõ, ½Å¿ì¿°, ½Å¿ì½Å¿°, ¹æ±¤¿°
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
´ÏÆ®·ÎǪ¶õÅäÀÎÀ¸·Î¼ º¸Åë ¼ºÀÎ 1ȸ 50 ~ 100mgÀ» 1ÀÏ 4ȸ ½ÄÈÄ ¹× Ãëħ½Ã¿¡ °æ±¸ Åõ¿©ÇÑ´Ù.
¿¬·É¡¤Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
- ¹«´¢Áõ, ÇÌ´¢°¡ Àִ ȯÀÚ
- ÁßÁõÀÇ ½Å±â´ÉÀåÇØ°¡ Àִ ȯÀÚ(Creatinine Clearance 40ml/mim ÀÌÇÏ)
- ÀÌ ¾à¿¡ ´ëÇÑ °ú¹ÎÁõÀÌ Àִ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
- ½ÅÀåÇØ, ºóÇ÷, ´ç´¢º´, ÀüÇØÁú ÀÌ»ó, ºñŸ¹Îºñ °áÇÌ ¹× ¼Ò¸ð¼º ÁúȯÀÌ Àִ ȯÀÚ
- °í·ÉÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
- Ç÷¾× :
µå¹°°Ô ¹éÇ÷±¸ °¨¼ÒÁõ, È£»ê±¸Áõ´Ù, ¿ëÇ÷¼º ºóÇ÷, °ÅÀû¾Æ±¸¼º ºóÇ÷ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.(ÁßÁö¿¡ µû¶ó Ç÷¾×»óÀº Á¤»óÀ¸·Î µ¹¾Æ¿Â´Ù.)
È£Èí±â°è :
°¡) ±Þ¼ºÆóÁõ»ó : µå¹°°Ô ¹ß¿, ¿ÀÇÑ, ±âħ, ÈäÅë, È£Èí°ï¶õ, X¼±»óÆóħÀ±»ó ¶ÇÇÑ Èä¼öÀú·ù»ó, È£»ê±¸Áõ°¡ µîÀ» ¼ö¹ÝÇÏ´Â Áõ»óÀÌ ³ªÅ¸³¯ ¶§°¡ ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
³ª) Àå±âÅõ¿© : µå¹°°Ô È£Èí°ï¶õ, Æó±â´ÉÀÌ»ó, °£Áú¼ºÆó¿°, Æó¼¶À¯Áõ µîÀÌ ³ªÅ¸³¯ ¶§°¡ ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ ÇÏ¿© ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ ¶§´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
½Å°æ°è : °¡²û µÎÅë, Çö±âÁõÀÌ ³ªÅ¸³ª°Å³ª µå¹°°Ô Á¹À½, ¸»ÃʽŰæÀåÇØ µîÀÌ ³ªÅ¸³¯ ¶§°¡ ÀÖ´Ù.
°£Àå : µå¹°°Ô Ȳ´Þ, °£±â´ÉÀåÇØ°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î Á¤±âÀûÀ¸·Î GOT, GPT µîÀÇ °üÂûÀ» ÇÏ¿© ÀÌ»óÀÌ ÀÖÀ» °æ¿ì Åõ¾àÀ» ÁßÁöÇÑ´Ù.
°ú¹ÎÁõ : µå¹°°Ô ¾Æ³ªÇʶô½Ã½º, ¾à¹°¿°, õ½ÄÀÇ ±â¿Õ·ÂÀÌ Àִ ȯÀÚÀÇ Ãµ½Ä¹ßÀÛ µî °ú¹ÎÁõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ÇǺΠ: °¡²û È«¹Ý, ½ÀÁø¾ç¹ßÁø, °¡·Á¿òÁõ, µÎµå·¯±â°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
À§Àå : ½Ä¿åºÎÁø, ±¸¿ª, ±¸Åä µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
±âŸ : µå¹°°Ô °üÀýÅë, Àϰú¼º Å»¸ð°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ÀÓºÎ, ¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿© ÀӽŠ¹× ¼öÀ¯ ±â°£ Áß¿¡ Åõ¿©¿¡ °üÇÑ ¾ÈÀü¼ºÀº È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ÀӺΠ¶Ç´Â Àӽа¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ ¹× ¼öÀ¯ ÁßÀÇ ºÎÀο¡°Ô´Â Ä¡·á»óÀÇ À¯ÀͼºÀÌ À§Ç輺À» »óȸÇÑ´Ù°í ÆÇ´ÜµÉ ¶§¸¸ Åõ¿©ÇÑ´Ù.
|
| »óÈ£ÀÛ¿ë |
´ÙÀ½ÀÇ °¢ ¾àÁ¦¿ÍÀÇ º´¿ë¿¡ µû¶ó ±× ÀÛ¿ëÀÌ Áõ° ¶Ç´Â °¨¼ÒµÇ´Â ¼ö°¡ ÀÖÀ¸¹Ç·Î ºÎµæÀÌ ÇÏ¿© Åõ¿©ÇÏ´Â °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
- Áõ°½ÃŰ´Â ¾àÁ¦ :
ÇÁ·Îº£³×½Ãµå, ¿äÀÇ pH¸¦ ³»¸®´Â ¾àÁ¦
°¨¼Ò½ÃŰ´Â ¾àÁ¦ : Á¦»êÁ¦, ¾Æ¼¼Å¸Á¹¾Æ¹Ìµå, ³¯¸®µð½Ä»ê Æä³ë¹Ù¸£ºñÅ» |
| ±âŸ |
- Àå±â Åõ¿©ÀÇ Çʿ䰡 ÀÖ´Â °æ¿ì¿¡´Â Á¤±âÀûÀ¸·Î ¼¼±ÕÀÇ °¨¼ö¼º½ÃÇè, ½Å±â´É °Ë»ç¸¦ ÇÔ°ú µ¿½Ã¿¡ °¨·®ÇÔÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
- º¹¿ëÁß ¿ä°¡´ÏÆ®·Î Ǫ¶õÅäÀÎÀÇ ´ë»ç¹°Áú¿¡ ÀÇÇÏ¿© Ȳ°¥»öÀ¸·Î º¯ÇÏ´Â ¼ö°¡ ÀÖÀ¸³ª »ý¸®ÀûÀ¸·Î Ưº°ÇÑ ¿µÇâÀº ¾ø´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
(ÀÓ»ó ½ÃÇè¿¡¼ ÀӽŠ3±â¿¡ À§Ç輺 º¸°íµÊ. -Briggs G, et al. Drugs in Pregnancy and Lactation 7th edit./ Contraindicated in women at term. Do not give to pregnant patient with G-6-PD deficiency. )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Nitrofurantoin¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Nitrofurantoin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Nitrofurantoin inhibits bacterial acetyl-coenzyme A, interfering with the organism's carbohydrate metabolism. The drug also can disrupt bacterial cell wall formation.
|
| Pharmacology |
Nitrofurantoin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Nitrofurantoin, a nitrofuran antibacterial agent, is available in microcrystalline and macrocrystalline form to treat urinary tract infections caused by many gram-negative and some gram-positive bacteria.
|
| Protein Binding |
Nitrofurantoin¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 60%
|
| Half-life |
Nitrofurantoin¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 0.3-1 hour
|
| Pharmacokinetics |
NitrofurantoinÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö :
- À§Àå°ü¿¡¼ Àß Èí¼öµÈ´Ù.
- °Å´ë °áÁ¤Çü Á¦ÇüÀº ¼¼È÷ ¿ëÇØµÇ¾î ´À¸®°Ô Èí¼öµÇ¾î À§Àå°ü ºÎÀÛ¿ëÀÌ Àû´Ù.
- »ýü³»ÀÌ¿ë·ü : À½½Ä¹° Á¸Àç½Ã Áõ°¡
- ºÐÆ÷ :
- ºÐÆ÷¿ëÀû : 0.8 L/kg
- ÅÂ¹Ý Åë°ú, À¯Áó ºÐºñ
- ´Ü¹é°áÇÕ : 40%±îÁö
- ´ë»ç : 60%°¡ Ç÷¾× ÀÌ¿ÜÀÇ Á¶Á÷¿¡¼ ºÒȰ¼ºÃ¼·Î ´ë»çµÈ´Ù.
- ¹Ý°¨±â : 20-60ºÐ, ½Å¼Õ»ó½Ã Áõ°¡
- ¼Ò½Ç :
- ´ë»çü ¹× ¹Ìº¯Èü°¡ ½Å¹è¼³ (40%)µÇ°í, ¼Ò·®ÀÌ º¯¹è¼³µÈ´Ù.
- »ç±¸Ã¼ ¿©°ú ¹× ¼¼´¢°ü ºÐºñ¸¦ ÅëÇØ ½Å¹è¼³µÈ´Ù.
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Nitrofurantoin¿¡ ´ëÇÑ Description Á¤º¸ A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression. [PubChem]
|
| Dosage Form |
Nitrofurantoin¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralTablet Oral
|
| Drug Category |
Nitrofurantoin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Infective Agents, UrinaryAnti-Infectives
|
| Smiles String Canonical |
Nitrofurantoin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ [O-][N+](=O)C1=CC=C(O1)C=NN1CC(=O)NC1=O
|
| Smiles String Isomeric |
Nitrofurantoin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ [O-][N+](=O)C1=CC=C(O1)/C=N\N1CC(=O)NC1=O
|
| InChI Identifier |
Nitrofurantoin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3-/f/h10H
|
| Chemical IUPAC Name |
Nitrofurantoin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1-[(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2012-03-02
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ¡Ã4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. NITROFURANTOIN[GGT Increase][Composite Activity](Score) A(Marginal) 0(Active) 5[Alkaline Phosphatase Increase](Activity Score) A(Number of Rpts) ¡Ã4(Index value) 32.8[SGOT Increase](Activity Score) A(Number of Rpts) ¡Ã4(Index value) 52[SGPT Increase](Activity Score) A(Number of Rpts) ¡Ã4(Index value) 27.4[LDH Increase](Activity Score) A(Number of Rpts) ¡Ã4(Index value) 35.6[GGT Increase](Activity Score) A(Number of Rpts) ¡Ã4(Index value) 16.4
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|